Clinical Trial Update: Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MK2206, an Akt inhibitor, in recurrent or advanced endometrial cancer; study completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Adenocarcinoma
• Endometrial Adenosquamous Carcinoma
• Endometrial Clear Cell Adenocarcinoma
• Endometrial Serous Adenocarcinoma
• Uterine Corpus Carcinoma

Drugs mentioned

• MK2206 (MK2206)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-09-05